San Diego - With careful use, smallpox vaccination programs can be implemented on a large scale, and dermatologists will play a big role in its execution by assisting local health departments and preparing their professional colleagues, according to information presented by Colonel John D. Grabenstein, R.Ph., Ph.D., at the recent Infectious Diseases Society of America's annual meeting, held here.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.